EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped Phase 2 study terminated due to insufficient enrollment and was not based on safety concerns. Novocure is enrolling a new Phase 3 study of TTFields as a first line treatment for advanced/metastatic NSCLC (NCT06216301).

Conditions

Non-small Cell Lung Cancer

Interventions

DEVICE: NovoTTF-200T
DRUG: Pembrolizumab (MK-3475) 200 mg

Sponsor

NovoCure GmbH

Collaborators

[object Object]